EMAIL THIS PAGE TO A FRIEND

Bioorganic & medicinal chemistry

Hologram QSAR model for the prediction of human oral bioavailability.


PMID 17870541

Abstract

A drug intended for use in humans should have an ideal balance of pharmacokinetics and safety, as well as potency and selectivity. Unfavorable pharmacokinetics can negatively affect the clinical development of many otherwise promising drug candidates. A variety of in silico ADME (absorption, distribution, metabolism, and excretion) models are receiving increased attention due to a better appreciation that pharmacokinetic properties should be considered in early phases of the drug discovery process. Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects. In the present work, hologram quantitative structure-activity relationships (HQSAR) were performed on a training set of 250 structurally diverse molecules with known human oral bioavailability. The most significant HQSAR model (q(2)=0.70, r(2)=0.93) was obtained using atoms, bond, connection, and chirality as fragment distinction. The predictive ability of the model was evaluated by an external test set containing 52 molecules not included in the training set, and the predicted values were in good agreement with the experimental values. The HQSAR model should be useful for the design of new drug candidates having increased bioavailability as well as in the process of chemical library design, virtual screening, and high-throughput screening.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

UC213
(R)-(+)-Warfarin, ≥97% (HPLC)
C19H16O4
375160
(S)-(+)-Ibuprofen, ReagentPlus®, 99%
C13H18O2
471909
(S)-(+)-Ketoprofen, 99%
C16H14O3
N4128
19-Norethindrone, ≥98%, powder
C20H26O2
301507
2-Mercapto-1-methylimidazole, ≥99%
C4H6N2S
F7129
5-Fluorocytosine, nucleoside analog
C4H4FN3O
P3755
6-Propyl-2-thiouracil, enzyme inhibitor
C7H10N2OS
27602
Caffeine, anhydrous, tested according to Ph.Eur.
C8H10N4O2
C6895
Cefaclor
C15H14ClN3O4S
C0253
Chlorambucil
C14H19Cl2NO2
C6643
Clofibrate, liquid
C12H15ClO3
N2260
D(−)-Norgestrel, analytical standard
C21H28O2
T2386
Δ9-Tetrahydrocannabinol solution, ethanol solution
C21H30O2
T4764
Δ9-Tetrahydrocannabinol solution, 1.0 mg/mL in methanol, analytical standard, for drug analysis
C21H30O2
46158
Dapsone, VETRANAL, analytical standard
C12H12N2O2S
D5878
Digitoxin, ≥92% (HPLC), powder
C41H64O13
G154
Gabapentin, solid
C9H17NO2
G117
Glipizide, solid
C21H27N5O4S
G2539
Glyburide, meets USP testing specifications
C23H28ClN3O5S
H4759
Hydrochlorothiazide, crystalline
C7H8ClN3O4S2
H2910
Hydrochlorothiazide, meets USP testing specifications
C7H8ClN3O4S2
M8506
Methimazole, analytical standard
C4H6N2S
N7878
Nitrofurantoin, crystalline
C8H6N4O5
46502
Nitrofurantoin, VETRANAL, analytical standard
C8H6N4O5
610305
Phencyclidine solution, 1 mg/mL in methanol, drug standard
C17H25N
P0847
Piroxicam, meets USP testing specifications
C15H13N3O4S
109185
Saccharin, ≥98%
C7H5NO3S
T5411
Testosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, drug standard